Concourse Financial Group Securities, Inc. Chemomab Therapeutics Ltd. Transaction History
Concourse Financial Group Securities, Inc.
- $1.52 Billion
- Q1 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CMMB
# of Institutions
16Shares Held
2.66MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA2.24MShares$2.04 Million0.04% of portfolio
-
Ikarian Capital, LLC Dallas, TX213KShares$194,1860.02% of portfolio
-
Two Sigma Investments, LP New York, NY40KShares$36,3940.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny37.8KShares$34,3980.0% of portfolio
-
Kestra Private Wealth Services, LLC31.2KShares$28,4290.0% of portfolio
About Chemomab Therapeutics Ltd.
- Ticker CMMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,431,700
- Market Cap $10.4M
- Description
- Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...